29
Jan

In this week’s EuroBiotech Report, Belgian biotech ThromboGenics, having seen its stock price peak at €45 two years ago, has experienced a series of share slides, the latest of which was triggered by its partner Novartis. And more.

…read more

Source: Novartis pins weak Jetrea sales on PhIII, KDEV CEO leaves after 3 months, Cantargia plans IPO

    

0 No comments